AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Phio Pharmaceuticals Corp. Statistics
Share Statistics
Phio Pharmaceuticals Corp. has 1.73M shares outstanding. The number of shares has increased by -29.1% in one year.
Shares Outstanding | 1.73M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 101.27% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.68M |
Failed to Deliver (FTD) Shares | 7.63K |
FTD / Avg. Volume | 2.07% |
Short Selling Information
The latest short interest is 51.49K, so 2.97% of the outstanding shares have been sold short.
Short Interest | 51.49K |
Short % of Shares Out | 2.97% |
Short % of Float | 3.07% |
Short Ratio (days to cover) | 0.5 |
Valuation Ratios
The PE ratio is -0.15 and the forward PE ratio is 0.08.
PE Ratio | -0.15 |
Forward PE | 0.08 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 0.2 |
P/FCF Ratio | -0.15 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Phio Pharmaceuticals Corp..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.
Current Ratio | 5.71 |
Quick Ratio | 5.71 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.4% and return on capital (ROIC) is -139.39%.
Return on Equity (ROE) | -1.4% |
Return on Assets (ROA) | -1.16% |
Return on Capital (ROIC) | -139.39% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.35M |
Employee Count | 8 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -70.91% in the last 52 weeks. The beta is 1.47, so Phio Pharmaceuticals Corp.'s price volatility has been higher than the market average.
Beta | 1.47 |
52-Week Price Change | -70.91% |
50-Day Moving Average | 2.61 |
200-Day Moving Average | 4.34 |
Relative Strength Index (RSI) | 40.38 |
Average Volume (20 Days) | 369.01K |
Income Statement
Revenue | n/a |
Gross Profit | -6.33M |
Operating Income | -10.82M |
Net Income | -10.83M |
EBITDA | -10.64M |
EBIT | n/a |
Earnings Per Share (EPS) | -46.87 |
Balance Sheet
The company has 8.49M in cash and 35.00K in debt, giving a net cash position of 8.46M.
Cash & Cash Equivalents | 8.49M |
Total Debt | 35.00K |
Net Cash | 8.46M |
Retained Earnings | -139.21M |
Total Assets | 5.87M |
Working Capital | 4.95M |
Cash Flow
In the last 12 months, operating cash flow was -10.75M and capital expenditures -5.00K, giving a free cash flow of -10.75M.
Operating Cash Flow | -10.75M |
Capital Expenditures | -5.00K |
Free Cash Flow | -10.75M |
FCF Per Share | -46.55 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
PHIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -2355.28% |
FCF Yield | -311.94% |
Analyst Forecast
The average price target for PHIO is $36, which is 1709% higher than the current price. The consensus rating is "Buy".
Price Target | $36 |
Price Target Difference | 1709% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 5, 2024. It was a backward split with a ratio of 1:9.
Last Split Date | Jul 5, 2024 |
Split Type | backward |
Split Ratio | 1:9 |
Scores
Altman Z-Score | -36.16 |
Piotroski F-Score | 2 |